Systems architecture study demonstrates governed capability acquisition in autonomous agent utility grids, indicating verifiable separation between discovery telemetry and settled commercial revenue.
Autonomous agents can invoke tools, but invocation alone does not define a market. Before software can economically acquire an external capability, it must discover a relevant operation, observe current price and requirements, determine whether payment is authorized, cross a payment boundary, receive an outcome, and preserve enough evidence to distinguish discovery from realized commercial activity. This preprint presents a capability-acquisition layer added to the SALT19 Agent Utility Grid after the earlier Governed Decision-Commerce Control Plane record (DOI 10.5281/zenodo.22102248). The new architecture introduces two free front-door capabilities (find-salt19-tool and salt19-pricing), twelve one-cent Fresh-State acquisition products, explicit qualified-demand telemetry, and a zero-spend public-market observer while preserving x402 v2 exact payments on Base mainnet with USDC and validated_external_revenue as the sole revenue authority. At the pinned evidence cutoff, source state was commit 39c5e0e2be09e57a59c6343a45468e3584e636a9 (2026-08-28T22:38:18Z). That exact revision completed the production deployment workflow successfully, including exact-revision validation, D1 migration checks, production Worker deployment, external-payability certification, live surface verification, comprehensive advertised production contracts, and zero-spend transaction readiness. Same-revision MCP Registry publication, Phase-1 live smoke, and registry public-identity synchronization also completed successfully. The paper explicitly distinguishes free selection, qualified discovery, payment capability, paid retry, settlement, and validated revenue. A crawler, registry probe, HTTP 402 challenge, free selection, or seller-run test is not treated as commercial success. Fresh-State source/fetch provenance is not represented as a signed Proof402 receipt unless the receipt finalizer actually creates one. The evidence is first-party production and source validation. This record does not claim product-market fit, generalized willingness-to-pay, repeat external buyers, optimal economic routing, external scientific replication, or a stable authoritative external tool count.
No takes yet. Share an insight, caveat, or question.
Gabriel Allit (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: